An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →. With Rigel Pharmaceuticals.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
164actual
Sites
54
Countries
Argentina, Czechia, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-23 | actual | When the study began enrolling |
| Primary completion | 2025-12-08 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-22 | actual | The whole study's end, after follow-up |
| First posted | 2023-05-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Rheumatoid Arthritis
Interventions
- Drug: LY3871801
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPhase 2a: Change from Baseline in Disease Activity Score - high-sensitivity C-reactive protein (DAS28-hsCRP)
measured Baseline, Week 12
Phase 2b: Percentage of Participants Achieving American College of Rheumatology (ACR)50
measured Baseline to Week 12
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed